Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The FDA has given its final approval for AstraZeneca's drug Arimidex for the adjuvant treatment of hormone receptor-positive early breast cancer in postmenopausal women.
Subscribe to our email newsletter
Arimidex is the only aromatase inhibitor with study results representing a full five years of efficacy and safety data in this primary adjuvant setting, and is now the only aromatase inhibitor that has proven superior disease-free survival over tamoxifen in the primary adjuvant setting.
This long-term data for Arimidex provides clinicians and patients an opportunity to make the most informed decision about their primary adjuvant therapy.
“We’re proud to provide doctors and patients with this critical, long-term information regarding Arimidex. The five-year profile of safety and efficacy is similar to that seen in the initial analysis with no new concerns arising from this mature data set,” said Dr Joseph Purvis, executive director medical science at AstraZeneca. Arimidex is currently the most widely prescribed aromatase inhibitor for breast cancer patients.